Subscribe

Stem Holdings, Inc. (STMH)

USD0.00 +0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address 2201 NW Corporate Boulevard 33431
Boca Raton, FL, US
CEO Matthew J. Cohen
Website stemholdings.com
IPO 2021-01-08
CIK 1697834 ISIN US85858U3059

Explore sections of this company profile

Also trades on Canadian Securities Exchange · STEM.CN (CAD) Other OTC · STMH (USD)
Description

Stem Holdings, Inc. operates as a fully integrated enterprise within the cannabis and technology sectors. Its core activities involve the cultivation, production, distribution, and sale of both cannabis and cannabis-derived products. The company manages a diverse brand portfolio, which includes TJ's Gardens, TravisxJames, and Yerba Buena for flower and extracts, as well as Cannavore for edible treats. For the broad consumer market, they offer Doseology, a CBD-focused brand. Additionally, their technological offerings comprise the e-commerce delivery platforms Budee and Ganjarunner. As of September 30, 2021, Stem Holdings possessed ownership interests in 29 state-issued cannabis licenses. Specifically, these included 9 cultivation permits, 3 processing permits, 2 wholesale distribution licenses, 3 hemp production licenses, 7 dispensary licenses, and 5 adult-use medical retail licenses. Established in 2016, the company's headquarters are located in Boca Raton, Florida.

Market Cap & Enterprise Value
Merger & Acquisition History
Target company Ticker Date Filing
SDA OTCQX 2020-12-28 View
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
134
Beta
0.79
Float Shares
6.67M
Free Float %
100.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +0.00% +0.00% +0.00% +0.00% +9,900.00% +0.00% -99.97% -100.00% -100.00% -100.00%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-16.99
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -100.0% Q3'23: -391.2% (vs Q3'22)
  • ✗
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +11.9% Q3'23: +906.9% (vs Q3'22)
  • ✗
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    — Q3'23: -3.1% (vs Q3'22)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    — Q3'23: -19.7% (vs Q3'22)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    -521.8% Q3'23: +1,243.3% (vs Q3'22)
  • ✗
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +11.9% Q3'23: -96.0% (vs Q3'22)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    -0.60× Q3'23: 0.25× (vs Q3'22)
Valuation Multiples From To
DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.79) × ERP
WACC = 0% × Ke + 100% × Kd (52.9%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 0.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Sep 2021
actual 		Sep 2022
actual 		Sep 2023
actual 		Sep 2026
1 Rev. Ana.
1 EPS Ana. 		Sep 2027
1 Rev. Ana.
1 EPS Ana. 		Sep 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
20.94M
est: 39.57M (-47.1%)
16.56M
est: 17.85M (-7.2%)
—
est: 801.88M (-100.0%)
39.57M
39.57M – 39.57M
-95.1% YoY
39.57M
39.57M – 39.57M
+0.0% YoY
17.85M
17.85M – 17.85M
-54.9% YoY
EBITDA
-6.08M
est: -5.93M (-2.5%)
329.0K
est: -2.68M (+112.3%)
-3.90M
est: -120.22M (+96.8%)
-5.93M
-5.93M – -5.93M
+95.1% YoY
-5.93M
-5.93M – -5.93M
+0.0% YoY
-2.68M
-2.68M – -2.68M
+54.9% YoY
EBIT
-8.32M
est: -9.31M (+10.6%)
-2.16M
est: -4.20M (+48.5%)
-3.90M
est: -188.67M (+97.9%)
-9.31M
-9.31M – -9.31M
+95.1% YoY
-9.31M
-9.31M – -9.31M
+0.0% YoY
-4.20M
-4.20M – -4.20M
+54.9% YoY
Net Income
-64.36M
est: -27.85M (-131.1%)
-17.37M
est: -15.19M (-14.3%)
-19.02M
est: -49.27M (+61.4%)
-27.85M
-27.85M – -27.85M
+43.5% YoY
-27.85M
-27.85M – -27.85M
+0.0% YoY
-15.19M
-15.19M – -15.19M
+45.5% YoY
SGA
17.93M
est: 87.72M (-79.6%)
6.69M
est: 39.56M (-83.1%)
3.75M
est: 1.78B (-99.8%)
87.72M
87.72M – 87.72M
-95.1% YoY
87.72M
87.72M – 87.72M
+0.0% YoY
39.56M
39.56M – 39.56M
-54.9% YoY
EPS
-40.27
est: -11.00 (-266.1%)
-6.72
est: -6.00 (-12.0%)
-5.92
est: -19.46 (+69.6%)
-11.00
-11.00 – -11.00
+43.5% YoY
-11.00
-11.00 – -11.00
+0.0% YoY
-6.00
-6.00 – -6.00
+45.5% YoY

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-23.76M
OE per share TTM
-237.36
Owner's Yield
-2,346,172.99%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
136.0%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
# Reporting person ⇅ Amount owned ⇅ % of class ⇅ Sole voting ⇅ Shared voting ⇅ Sole dispositive ⇅ Shared dispositive ⇅ Type Citizenship Filing date ⇅ SEC filing
1 Berk 2.58M 5.15% 2.58M — 2.58M 10.00 IN USA 2019-10-25 ↗
2 Groussman 833.3K 9.00% 833.3K — 833.3K 10.00 CO USA 2018-06-14 ↗
3 Mark Groussman 833.3K 9.00% 833.3K — 833.3K — CO USA 2018-07-13 ↗

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
10.00M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+10,000,000
Insider buys vs sells (history) From To
Recent insider transactions From To
Date Person Role Transaction A/D Security Shares Price Value Owned after D/I Filing
2023-06-30 Rai Rajiv Director A-Award A Common Stock 5,000,000 0.01 50.0K 7,494,853 — ↗
2023-04-05 COHEN MATTHEW Director / Officer A-Award A Common Stock 10,000,000 0.01 140.0K 11,359,961 — ↗
2022-12-01 Rai Rajiv Director A-Award A Common Stock 162,500 0.02 3.3K 2,332,353 — ↗
2022-09-30 Rai Rajiv Director A-Award A Common Stock 2,169,853 0.03 65.1K 2,169,853 — ↗
2022-07-19 Rai Rajiv Director A-Award A Common Stock 162,500 0.02 3.3K 2,494,853 — ↗
2022-04-21 COHEN MATTHEW Director / Officer A-Award A Common Stock 359,961 0.06 21.6K 1,359,961 — ↗
2022-03-30 COHEN MATTHEW Director / Officer — I Common Stock 0 0.00 — 359,961 — ↗
2021-07-16 Hubbard Steven Shelly Director / Officer A-Award A Common Stock 124,495 0.38 47.3K 853,007 — ↗
2021-06-25 Hayek Brian John Director — D Common Stock 0 0.00 — 4,337,752 — ↗
2021-06-25 Diener Robert Louis Benjamin Director — D Common Stock 0 0.00 — 68,000 — ↗
2021-06-11 Suskind Dennis Director A-Award A Options 250,000 0.40 100.0K 250,000 — ↗
2021-03-31 Suskind Dennis Director A-Award A Common Stock 62,500 0.45 28.1K 450,000 — ↗
2021-02-03 Berk Adam Director / Officer A-Award A Common Stock 225,000 0.83 186.8K 7,448,174 — ↗
2020-12-30 Suskind Dennis Director A-Award A Common Stock 62,500 0.45 28.1K 387,500 — ↗
2020-11-05 Berk Adam Director / Officer A-Award A Common Stock 3,200,000 0.30 960.0K 7,223,174 — ↗
2020-09-30 Suskind Dennis Director A-Award A Common Stock 62,500 0.43 26.9K 325,000 — ↗
2020-07-21 Berk Adam Director / Officer A-Award A Common Stock 318,822 0.41 130.7K 2,897,038 — ↗
2020-07-21 Bender Garrett Martin Director A-Award A Common Stock 659,532 0.74 488.1K 4,384,504 — ↗
2020-07-17 Berk Adam Director / Officer A-Award A Common Stock 30,000 0.41 12.3K 3,021,498 — ↗
2020-07-17 Bender Garrett Martin Director A-Award A Common Stock 19,346 0.74 14.3K 3,695,628 — ↗
2020-06-30 Suskind Dennis Director A-Award A Common Stock 62,500 0.42 26.3K 262,500 — ↗
2020-06-01 Hubbard Steven Shelly Director / Officer A-Award A Options 100,000 0.52 52.0K 200,000 — ↗
2020-05-31 Hayek Brian John Director — D Stock Purchase Warrant 500,000 0.50 250.0K 0 — ↗
2020-03-31 Suskind Dennis Director A-Award A Common Stock 62,500 0.40 25.0K 200,000 — ↗
2020-01-16 Bender Garrett Martin Director A-Award A Common Stock 19,346 0.76 14.7K 3,646,938 — ↗
2020-01-14 Suskind Dennis Director A-Award A Options 250,000 1.00 250.0K 250,000 — ↗
2020-01-01 Suskind Dennis Director — D Common Stock 0 0.00 — 0 — ↗
2019-12-31 Suskind Dennis Director A-Award A Common Stock 62,500 0.44 27.5K 137,500 — ↗
2019-11-27 Bender Garrett Martin Director A-Award A Common Stock 27,737 0.75 20.8K 3,627,592 — ↗
2019-11-04 Diener Robert Louis Benjamin Director — D Common Stock Purchase Warrant 50,000 0.50 25.0K 0 — ↗
2019-10-01 Snider Lindy L Director J-Other A Common Stock 159,044 0.90 143.1K 159,044 — ↗
2019-10-01 Sinder Lindy L Director J-Other A Common Stock 117,378 0.90 105.6K 159,044 — ↗
2019-10-01 Hubbard Steven Shelly Director J-Other A Common Stock 510,179 0.90 459.2K 728,512 — ↗
2019-10-01 Feingold Jessica Michelle Director J-Other A Common Stock 78,660 0.90 70.8K 93,863 — ↗
2019-10-01 Berk Adam Director / Officer J-Other A Common Stock 1,563,350 0.90 1.41M 2,578,216 — ↗
2019-10-01 Bender Garrett Martin Director A-Award A Common Stock 51,589 0.75 38.7K 3,599,855 — ↗
2019-09-10 Bender Garrett Martin Director A-Award A Common Stock 3,301,914 0.76 2.51M 3,548,266 — ↗
2019-06-16 Berk Adam Director / Officer A-Award A Common Stock 300,000 1.61 483.0K 1,014,866 — ↗
2019-06-04 Hubbard Steven Shelly Director A-Award A Common Stock 50,000 1.61 80.5K 218,333 — ↗
2019-06-01 Hubbard Steven Shelly Director / Officer A-Award A Options 100,000 1.40 140.0K 100,000 — ↗
2019-05-20 Raj Rajiv Director — D Stock Options 50,000 2.40 120.0K 0 — ↗
2019-05-07 Suskind Dennis Director A-Award A Common Stock 75,000 0.42 31.5K 75,000 — ↗
2019-03-18 Feingold Jessica Michelle Director A-Award A Common Stock 4,787 1.65 7.9K 15,203 — ↗
2019-03-04 Berk Adam Director / Officer A-Award A Options 200,000 0.10 20.0K 200,000 — ↗
2018-12-31 Hayek Brian John Director — D Employee Stock Option (right to buy) 12/28/2018 Grant 1,538,910 0.10 153.9K 0 — ↗
2018-08-16 Hubbard Steven Shelly Director A-Award A Common Stock 50,000 2.40 120.0K 168,333 — ↗
2018-08-16 Berk Adam Director / Officer A-Award A Common Stock 300,000 2.40 720.0K 714,886 — ↗
2018-07-23 Hubbard Steven Shelly Director A-Award A Common Stock 50,000 2.40 120.0K 118,333 — ↗
2018-07-16 Berk Adam Director / Officer A-Award A Common Stock 100,000 2.40 240.0K 414,886 — ↗
2018-06-01 Snider Lindy L Director A-Award A Options 50,000 2.40 120.0K 50,000 — ↗
2018-06-01 Sinder Lindy L Director A-Award A Stock Option 50,000 2.40 120.0K 100,000 — ↗
2018-06-01 Hubbard Steven Shelly Director A-Award A Stock Option 100,000 2.40 240.0K 300,000 — ↗
2018-06-01 Berk Adam Director / Officer A-Award A Stock Option 50,000 2.40 120.0K 100,000 — ↗
2018-06-01 Bender Garrett Martin Director A-Award A Stock Option 50,000 2.40 120.0K 100,000 — ↗
2018-02-15 Feingold Jessica Michelle Director — D Stock Option 50,000 2.40 120.0K 0 — ↗
2018-01-09 Sinder Lindy L Director P-Purchase A Common Stock 41,666 2.40 100.0K 41,666 — ↗
2017-08-09 Hubbard Steven Shelly Director A-Award A Common Stock 50,000 2.40 120.0K 68,333 — ↗
2017-08-09 Berk Adam Director / Officer A-Award A Common Stock 100,000 2.40 240.0K 314,886 — ↗
2017-06-01 Sinder Lindy L Director A-Award A Stock Option 50,000 2.40 120.0K 50,000 — ↗
2017-06-01 Hubbard Steven Shelly Director A-Award A Stock Option 100,000 2.40 240.0K 100,000 — ↗
2017-06-01 Berk Adam Director / Officer A-Award A Stock Option 50,000 2.40 120.0K 50,000 — ↗
2017-06-01 Bender Garrett Martin Director A-Award A Stock Option 50,000 2.40 120.0K 50,000 — ↗
2016-06-06 Sinder Lindy L Director — D Common Stock 0 0.00 — 0 — ↗
2016-06-06 Hubbard Steven Shelly Director / Officer — D Common Stock 0 0.00 — 18,333 — ↗
2016-06-06 Berk Adam Director / Officer — D Common Stock 0 0.00 — 214,886 — ↗
2016-06-06 Bender Garrett Martin Director — D Common Stock 0 0.00 — 128,974 — ↗

Executive team

Top executives
Shares Outstanding
6.67M

Executive compensation

Executive compensation (annual)
# Year ⇅ Executive ⇅ Salary ⇅ Bonus Stock award ⇅ Option award Incentive Other Total ⇅ % Stock-
based ⇅		 Filing
1 2021 Adam Berk CEO 300.0K — 540.0K — — — 840.0K 64.29% ↗
2 2021 Ellen B. Deutsch EVP & COO 253.0K — — — — — 253.0K 0.00% ↗
3 2021 Dennis Suskind Director — — 93.8K 100.0K — — 193.8K 100.00% ↗
4 2021 Steven Hubbard CFO 75.0K — — — — — 75.0K 0.00% ↗
5 2021 Brian Hayek Director 35.0K — — — — — 35.0K 0.00% ↗
6 2021 Robert Diener Director 30.0K — — — — — 30.0K 0.00% ↗
7 2021 Salvador Villanueva Director 21.9K — — — — — 21.9K 0.00% ↗
8 2020 Ellen B. Deutsch EVP & COO 240.0K — 82.0K 26.0K — — 348.0K 31.03% ↗
9 2020 Adam Berk CEO 300.0K — — — — — 300.0K 0.00% ↗
10 2020 Steven Hubbard CFO 45.0K — 26.0K 21.0K — — 92.0K 51.09% ↗
11 2020 Dennis Suskind Director — — 16.3K 35.2K — — 51.4K 100.00% ↗
12 2020 Robert Diener Director 30.0K — — — — — 30.0K 0.00% ↗
13 2018 Director Jennifer Michelle Feingold 112.5K — 25.0K 97.5K — — 235.0K 52.13% ↗
14 2018 Director Lindy Snider — — — 117.4K — — 117.4K 100.00% ↗
15 2018 Director Garrett Bender — — — 117.4K — — 117.4K 100.00% ↗
16 2017 Director Lindy Snider — — — 56.0K — — 56.0K 100.00% ↗
17 2017 Director Garrett Bender — — — 56.0K — — 56.0K 100.00% ↗
18 2017 Director Rajiv Rai — — — — — — — — ↗
19 2017 Director Jennifer Michelle Feingold — — — — — — — — ↗
20 2016 Director Jennifer Michelle Feingold — — — — — — — — ↗
21 2016 Director Rajiv Rai — — — — — — — — ↗
22 2016 Director Garrett Bender — — — — — — — — ↗
23 2016 Director Lindy Snider — — — — — — — — ↗
CEO compensation breakdown

Proxy statements

Proxy statements (DEF 14A)
Filing date Form type Filing
2022-12-05 DEF 14A ↗
2022-11-25 PRE 14A ↗
2021-05-07 PRE 14A ↗

Recent SEC filings

Recent SEC filings
Filing date Form type Filing
2024-09-16 15-12G/A ↗
2024-07-02 15-12G ↗
2024-05-24 10-K ↗
2024-02-01 8-K ↗
2023-12-29 NT 10-K ↗
2023-12-01 8-K ↗
2023-09-08 4 ↗
2023-08-21 10-Q ↗
2023-08-15 NT 10-Q ↗
2023-05-22 10-Q ↗

Executive team

NameTitleCompensationGender
Matthew J. Cohen Co-Founder, President, Chief Executive Officer, Chief Financial Officer & Director 250.0K male
Robert Louis-Benjamin Diener General Counsel, Secretary & Independent Director 30.0K male
Mauria Betts Director of Branding & Public Relations — —
ESG Rating
B
DRUG MANUFACTURERS - SPECIALTY & GENERIC
2023
E (Environmental)
57.7 / 66.0
Company / Sector avg.
S (Social)
61.3 / 70.0
Company / Sector avg.
G (Governance)
65.0 / 66.6
Company / Sector avg.
ESG Total
61.3 / 67.5
Company / Sector avg.
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic